Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 564 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Conditioning Clear all
Completed No phase listed Observational Accepts healthy volunteers

To Compare the Ischemic Pre-conditioning and Post-conditioning on Reperfusion Injury in Humans.

NCT00385151
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
15 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 20, 2026, 1:40 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma

NCT06617286
View directory record Official record
Conditions
Classical Hodgkin Lymphoma
Interventions
CD30 CAR T-cell
Biological
Lead sponsor
New York Medical College
Other
Eligibility
6 Years to 29 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 20, 2026, 1:40 PM EDT
Completed Phase 1Phase 2 Interventional

Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases

NCT00056966
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
ANTI-CD45, CAMPATH-1H, FK506, Fludarabine, Total Body Irradiation, Stem cell infusion
Drug · Radiation · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2012 · Synced Oct 20, 2026, 1:40 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

RCT Comparing ESWT With PRP for Plantar Fasciitis in High Demand Cohort

NCT02668510
View directory record Official record
Conditions
Fasciitis, Plantar
Interventions
platelet rich plasma, Normal saline
Biological · Drug
Lead sponsor
Edna Rath
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 20, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders

NCT01050855
View directory record Official record
Conditions
Non Malignant Diseases, Immunodeficiencies, Hemoglobinopathies
Interventions
Reduced-Intensity Conditioning
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 25 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 20, 2026, 1:40 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Operant Conditioning for Rehabilitation After Stroke

NCT05020080
View directory record Official record
Conditions
Stroke
Interventions
Operant conditioning of motor evoked potentials
Other
Lead sponsor
University of Houston
Other
Eligibility
40 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 20, 2026, 1:40 PM EDT
Completed Phase 1 Interventional

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

NCT00880815
View directory record Official record
Conditions
CD20 Positive, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, T-Cell Non-Hodgkin Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bendamustine, Filgrastim, Fludarabine, Methotrexate, Rituximab, Tacrolimus
Procedure · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 20, 2026, 1:40 PM EDT
Terminated Phase 1 Interventional Results available

A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies

NCT02354417
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Biological: ProHema-CB
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
1 Year to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Duarte, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 20, 2026, 1:40 PM EDT
Completed Phase 2 Interventional

Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00006350
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
daclizumab, therapeutic allogeneic lymphocytes, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 20, 2026, 1:40 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector

NCT05432310
View directory record Official record
Conditions
Adenosine Deaminase Severe Combined Immune Deficiency
Interventions
A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
1 Month and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 20, 2026, 1:40 PM EDT
Terminated Phase 3 Interventional Results available

Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma

NCT02137096
View directory record Official record
Conditions
Recurrent Nasopharynx Carcinoma
Interventions
Etoposide phosphate, Carboplatin, Ifosfamide, Autologous Stem Cell Transplantation
Drug · Procedure
Lead sponsor
University of Florida
Other
Eligibility
2 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 20, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

NCT03406962
View directory record Official record
Conditions
Inherited Metabolic Disorders (IMD)
Interventions
MGTA-456
Drug
Lead sponsor
Magenta Therapeutics, Inc.
Industry
Eligibility
0 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Minneapolis, Minnesota • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 20, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

NCT00992446
View directory record Official record
Conditions
Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Non-Hodgkin Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, Carmustine, Cytarabine, Etoposide, Melphalan, Rituximab, Vorinostat
Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 20, 2026, 1:40 PM EDT
Terminated Phase 1 Interventional

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

NCT03240861
View directory record Official record
Conditions
HLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm, NY-ESO-1 Positive, Unresectable Malignant Neoplasm, Sarcoma
Interventions
18F-FHBG, Aldesleukin, Busulfan, Cellular Therapy, Computed Tomography, Filgrastim, Fludarabine, Leukapheresis, Plerixafor, Positron Emission Tomography
Other · Biological · Drug + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
16 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 20, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pain Modulatory Profiles in Massage for Healthy Participants

NCT03490474
View directory record Official record
Conditions
Healthy, Musculoskeletal Pain
Interventions
Pain Inducing Massage, Pain Free Massage, Coldpressor
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 20, 2026, 1:40 PM EDT
Terminated Phase 3 Interventional

Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia

NCT00002961
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, cyclosporine, etoposide, methotrexate, allogeneic bone marrow transplantation, Total Body Irradiation, Busulfan, Mesna, Radiation
Drug · Procedure · Radiation
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 21 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
17
States / cities
Birmingham, Alabama • San Diego, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2013 · Synced Oct 20, 2026, 1:40 PM EDT
Terminated No phase listed Observational

Social Anxiety Virtual Reality Study

NCT04288180
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
No intervention
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 20, 2026, 1:40 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Siplizumab for Sickle Cell Disease Transplant

NCT06078696
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Siplizumab, Exchange Transfusion, Total Body Irradiation, Stem Cell Infusion, Cyclophosphamide 50mg, Mesna, Sirolimus Oral Tablet, Rituximab or Biosimilar
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 20, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes

NCT00509288
View directory record Official record
Conditions
Melanoma, Skin Cancer
Interventions
autologous anti-MART-1 F5 T-cell receptor, Cyclophosphamide, Fludarabine, Aldesleukin, autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 28, 2012 · Synced Oct 20, 2026, 1:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ischemic Conditioning During Air tRansport Save penUmbral Tissue

NCT03481205
View directory record Official record
Conditions
Acute Stroke
Interventions
Ischemic conditioning device
Device
Lead sponsor
Enrique Leira
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 20, 2026, 1:40 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies

NCT05201183
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes
Interventions
Fludarabine + Total Marrow Irradiation
Combination Product
Lead sponsor
Naoyuki G. Saito, M.D., Ph.D.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 20, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Promoting Food Acceptance Through Positive Parenting: the Play and Grow Study

NCT06074926
View directory record Official record
Conditions
Obesity, Childhood, Overweight, Childhood, Overnutrition, Pediatric Obesity, Eating, Healthy
Interventions
Associative Conditioning, Repeated Exposure
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
3 Years to 5 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 20, 2026, 1:40 PM EDT
Active, not recruiting Phase 2 Interventional

Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia

NCT04262843
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome
Interventions
Cyclophosphamide, Fludarabine, Fludarabine Phosphate, Granulocyte Colony-Stimulating Factor, Hematopoietic Cell Transplantation, Intensity-Modulated Radiation Therapy, Mycophenolate Mofetil, Tacrolimus
Drug · Biological · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 1:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epi-Genetic Modulators of Fear Extinction in Alcohol Dependence

NCT02438969
View directory record Official record
Conditions
Fear, Stress, Alcohol Dependence
Interventions
Not listed
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 1:40 PM EDT